AI can help design AI systems: automating architecture choices, discovering algorithms, and optimizing hardware ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

The lack of gains in productivity from AI could stall adoption and burst the economic bubble. Is there a rational explanation?

This article, presented in the backdrop of the debates on the state of political theory in India, argues that the terms of debate need to shift to include the question of method of doing political ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Imagine Jo: Everyone in Jo's life recognizes her as an outstanding problem solver. She's the type of person who seems capable ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

The NFL playoffs are one week away and most of the field is set entering Week 18. Here's what to know about the postseason ...